MedPage Today) — TORONTO — A quadruplet regimen elicited favorable outcomes in an older population of transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM), according to phase II trial data.
The study of daratumumab…
Quadruplet Promising in Older Patients With Transplant-Ineligible Multiple Myeloma

Leave a Comment Leave a Comment